Half of FDA’s 2025 approvals targeted rare diseases. Real-world data made the difference.🧬
In 2025, rare diseases dominated the FDA approval portfolio: 26 of 46 novel drugs approved addressed rare or orphan disease indications. That’s consistent with a five-year trend—but this year was different. 📈
Why? The FDA’s Rare Disease Evidence Principles (RDEP) framework—introduced in March 2025 and operationalized in September—fundamentally shifted what counts as approvable evidence. For ultra-rare genetic diseases with <1,000 US patients, a single well-controlled trial plus robust supporting data (registries, natural history studies, real-world evidence) now meets FDA approval standards.
What this means: If you’re building rare disease therapies, the regulatory pathway is clearer—but the data requirement is non-negotiable. RDEP doesn’t lower the bar; it redirects it toward real-world, longitudinal patient outcomes as proof of efficacy.
Clinakos‘ role? We aggregate, de-risk, and activate rare disease real-world data—turning fragmented patient cohorts into approvable evidence that the FDA expects. 💡
The 95% treatment gap remains (only 5% of rare diseases have approved therapies). The infrastructure to close it? It’s here. The question: Do you have the data?
Building a rare disease program? Let’s discuss how RWD can strengthen your approval path. 📩
👉 Follow Clinakos Inc.
